Volume 6 Supplement 2

Current and new antitumor necrosis factor agents in perspective

Reviews

Edited by Peter E Lipsky and Ravinder N Maini

Supported by an educational grant from Centocor, Inc.

  1. Review

    Does safety make a difference in selecting the right TNF antagonist?

    Tumor necrosis factor (TNF) antagonists are biologic response modifiers that have significantly improved the outcomes in patients with rheumatoid arthritis (RA). At this report, safety data were collected on a...

    Roy Fleischmann and David Yocum

    Arthritis Research & Therapy 2004 6(Suppl 2):S12

    Published on: 21 June 2004

  2. Review

    Effective use of TNF antagonists

    Tumor necrosis factor (TNF) antagonists are biologic response modifiers that have significantly improved functional outcomes in patients with rheumatoid arthritis (RA). RA is a progressive disease in which str...

    David Yocum

    Arthritis Research & Therapy 2004 6(Suppl 2):S24

    Published on: 21 June 2004

  3. Review

    Expanding the armamentarium for the spondyloarthropathies

    Ankylosing spondylitis (AS) is a member of the family of spondyloarthropathies, which are inflammatory arthritides largely involving the axial skeleton and commonly accompanied by peripheral arthritis. Genetic...

    Paul M Peloso and Jürgen Braun

    Arthritis Research & Therapy 2004 6(Suppl 2):S36

    Published on: 21 June 2004

  4. Review

    Do anti-TNF agents have equal efficacy in patients with rheumatoid arthritis?

    Tumor necrosis factor (TNF) antagonists have dramatically improved the outcomes of rheumatoid arthritis (RA). Three agents currently available in the USA – infliximab, etanercept, and adalimumab – have been de...

    Sergio Schwartzman, Roy Fleischmann and G James Morgan

    Arthritis Research & Therapy 2004 6(Suppl 2):S3

    Published on: 21 June 2004

  5. Review

    Treating psoriatic arthritis: how effective are TNF antagonists?

    Psoriatic arthritis (PsA) is a seronegative spondyloarthropathy that commonly appears after the onset of the characteristic cutaneous lesions. This complication affects about 40% of patients with moderate to s...

    Alice B Gottlieb and Christian E Antoni

    Arthritis Research & Therapy 2004 6(Suppl 2):S31

    Published on: 21 June 2004

Logo

Advertisement